Dividends Inside 
Eli Lilly and Company
LLY
$1,183.16 (+ $3.00 + 0.25%)
Last updated: 2026-08-18 03:00 UTC
Eli Lilly and Company trades under ticker LLY on NYSE as a stock. Use this page to review stock price, share price, dividends, and price history. The page also shows Healthcare exposure. Identifiers: ISIN US5324571083, CUSIP 532457108. Also searched as Eli Lilly and.
Related researchLLY stock priceLLY share priceLLY dividend historyLLY dividend yieldEli Lilly and dividend historyEli Lilly and dividend yield532457108Eli Lilly and stockEli Lilly and share price
About the Company
Eli Lilly and Company is a global pharmaceutical company focused on discovering, developing, manufacturing, and marketing prescription medicines for human health. Headquartered in Indianapolis, Indiana, and founded in 1876, the company operates in therapeutic areas that include diabetes, obesity, oncology, immunology, neuroscience, and other specialty conditions. Eli Lilly and Company’s portfolio features innovative treatments for metabolic diseases, cancer, autoimmune disorders, and neurological conditions, supported by a broad pipeline of biologics, small molecules, and next-generation therapies. The company conducts research and clinical development across multiple geographies and manufactures medicines through facilities in the United States, Puerto Rico, Europe, and Asia, distributing its products in around 90 countries. Eli Lilly and Company plays a significant role in the healthcare system by working with physicians, hospitals, payers, and governments to make its therapies available to patients worldwide, while maintaining a single core business segment centered on human pharmaceutical products.
Price History
Latest News for LLY
What Kroger (KR)'s New Zepbound Access and Premium Ice Cream Push Means For Shareholders
Kroger recently expanded its offerings by rolling out Cold Case Ice Cream across more than 1,000 banner stores and, earlier this month, its pharmacies began offering Eli Lilly’s Zepbound KwikPen weight-management medication with access to various support and savings programs, alongside affirming a quarterly dividend of US$0.35 per share payable on June 1, 2026. Together, these moves highlight Kroger’s push to pair premium, differentiated grocery products with enhanced healthcare and pharmacy...
Gilead to Buy Ouro Medicines for $2.2 Billion. Why the Deal Is Key to Future Stock Gains.
Gilead plans to develop Ouro’s lead drug candidate, gamgertamig, alongside a Belgian pharma company.
Want to Buy the Dip on Eli Lilly? Consider This Low-Cost Vanguard ETF
After nearly tripling between 2023 and the end of 2025, Lilly is undergoing a steep sell-off in 2026.
Regional Bank Stock Up 33% as $3.7 Million Exit Tells a Different Story
First Bancorp delivers banking, lending, and digital financial services across the Carolinas, serving individuals and local businesses.
Top Analyst Reports for Eli Lilly, RTX & Abbott
Eli Lilly leads top analyst picks as GLP-1 demand, pipeline advances, and global growth momentum drive strong outlook despite rising competition risks.
With Two Companies Dictating Everything, IHE Is Riskier Than Most Investors Realize
Half of every dollar invested in iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE) rides on just two companies pulling in opposite directions in 2026. With a 0.38% expense ratio, nearly $1.1 billion in net assets, and a 20-year track record dating to May 2006, it offers income-oriented and sector investors a focused vehicle for pharmaceutical exposure. Focused ... With Two Companies Dictating Everything, IHE Is Riskier Than Most Investors Realize